Moira Gunn
BioTech Nation ... with Dr. Moira Gunn
Welcome to BIOTECH NATION !!! With understandable interviews requiring no background in science, BTN attracts a wide global audience. From everyday people looking for hope in treatments in development, to bioentrepreneurs interested in the experience of their fellow travelers, to venture capitalists looking for possibilities in cutting-edge breakthroughs, to scientists simply interested in the work of others, BioTech Nation is the voice of human endeavor, driving science to new realities for everyone. These interviews are drawn directly from the public radio program, "Tech Nation", which also...
Visita il sito del podcast e sostieni chi lo crea: biotechnation.com
Dove ascoltare?
I podcast nell'app Replaio Radio In arrivoI podcast stanno per arrivare nell'app. Installala ora e scopri per primo un modo tutto nuovo di vivere i podcast
Episodi
Chemistry All Around Us...Dr. Ijeoma Uchegbu, Author, "Chain Reaction" 17.11.2026 19:53
On this week's BioTech Nation, Moira speaks with Dr. Ijeoma Uchegbu, President of Wolfson College at the University of Cambridge, and Co-Founder & Chief Scientific Officer of Nanomerics, about how chemistry is all around us, all the time. Her book, "Chain Reaction: How Chemistry Shapes Us and Our World" delves into the chemical bonds and reactions that make up life as we know it.
Engineering the Future of Fertilizer...Dr. Tim Schnabel, Founder & CEO, Switch Bioworks 10.11.2026 28:05
On this episode of Biotech Nation, Dr. Tim Schnabel talks about how Switch Bioworks aims to revolutionize the fertilizer industry by engineering special microbes in place of chemical fertilizers. With a biotech approach, they hope to reduce the cost and environmental impact of industrial fertilizers, and they're already working with the USDA and EPA on trials.
2005 Interview with Elizabeth Holmes, Founder & Former CEO of Theranos 03.11.2026 20:56
On this episode of BioTech Nation, we look back at the first on-record interview with Theranos founder Elizabeth Holmes, recorded at KQED studios in 2005. At the time of the interview, Holmes was just 21 years old, and her company had already received almost $6 million in funding from investors. Now, over two decades have passed, and Elizabeth Holmes is serving time in prison for fraud. Revisiting...
Redefining Early Intervention for Heart Attacks...Dr. Harry Selker & Dr. Atul Deshpande, Immediate Therapeutics 27.10.2026 20:31
On this episode of BioTech Nation... Dr. Harry Selker & Dr. Atul Deshpande of Immediate Therapeutics speak with Moira about a new treatment that could be administered to heart attack patients right away...potentially before they even arrive at the hospital. Already successfully tested in Phase 2, it’s ready to go into final pivotal trials in Ambulances and Emergency Rooms.
AI-Powered Biology...Dr. Shana Kelley, President of Bioengineering & Head of Biohub Chicago 20.10.2026 25:24
This week on BioTech Nation, what is AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering and Head of Biohub, Chicago for the Chan-Zuckerberg Initiative, discusses how AI can be used to accelerate research, interpret data, and transform how new discoveries are made.
Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals 13.10.2026 19:24
This week on Biotech Nation, Heather Turner of LB Pharmaceuticals joins to discuss a drug that’s new to the US, but not-so-new to Europe, where it’s already been in use for a couple of years. Intended for managing neuropsychiatric conditions like Schizophrenia, the drug is taken by several million people, but the approval process in the US has had to start back at square one. We look at why that i...
From Film to Biotech...Toshi Iida, Chairman, FUJIFILM Biotechnologies 06.10.2026 16:37
When you think of FUJIFILM, you might be picturing rolls of camera film...but it turns out that's not all they've been working on. FUJIFILM Biotechnologies Chairman Toshi Iida joins to share more about how they're innovating in the world of biotech.
Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics 29.09.2026 18:07
What if chemotherapy could be delivered in a focused way, directly to a tumor, and only where it's needed? Intensity Therapeutics Founder, President, & CEO Lew Bender shares how they're working to change how chemotherapy is delivered to solid tumors, personalized for each patient, with the hopes of reducing the toll it takes on the body.
A New Path Forward for Cell Therapy...Jeff Liter, Founder & CEO, Luminary Therapeutics 22.09.2026 7:52
This week on BioTech Nation, Jeff Liter of Luminary Therapeutics shares how his team is taking a new approach to advanced cell therapy, in the hopes of making it more accessible and affordable. Rather than formulating a custom treatment using a patient's own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases...
Paving the Way for Miracle Drugs...Barry Werth, Author, "The Age of Cures" 15.09.2026 40:07
On this episode of Biotech Nation...the story of how the United States' pharmaceutical industry came to be, and the people behind it all. Barry Werth joins Moira to discuss his new book, “The Age of Cures: How American Scientists Saved Your Life", about a handful of individuals who revolutionized research and helped build the drug development ecosystem we have today.
A Different Approach to Treating Gout...Dr. James Mackay, Co-Founder, CEO, & President, Crystalys Therapeutics 08.09.2026 14:52
On this episode of BioTech Nation...Dr. James Mackay joins to talk about the progress Crystalys Therapeutics is making in the treatment of gout - a disease that affects more than 13 million people in the United States alone. Dr. Mackay debunks some common misconceptions surrounding the disease, and explains what Crystalys is doing to change the way doctors treat gout going forward.
The Potential of Peptide Drugs...Dr. Karsten Eastman, Co-Founder & CEO, Sethera Therapeutics 01.09.2026 20:08
You've probably heard of Peptides...but what exactly are they? And how do we know which ones are effective, and safe? Dr. Karsten Eastman, Co-Founder and CEO of Sethera Therapeutics, joins to answer all our questions about Peptides, and to tell us about Sethera's latest efforts to enhance peptides to make new medicines. Their plan: to develop a drug using enhanced peptides for Triple-Negative Bre...
Injectable Ice for Chronic Pain? Sameer Sabir, Co-Founder & CEO, Brixton Biosciences 25.08.2026 13:42
This week on BioTech Nation, Sameer Sabir, CEO of Brixton Biosciences, shares how their breakthrough injectable cold therapy, Neural Ice, could offer lasting relief for osteoarthritis pain. With a drug-free, nerve-targeting approach currently in clinical trials, this innovation may change how we treat joint pain without pills or repeated steroid injections.
Healing Hard-to-treat Wounds Faster?? Dr. Ned Swanson, Co-Founder, President & Chief Medical Officer, Polarity Bio 18.08.2026 14:23
Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.
Stem Cell Therapy for Congenital Heart Defects...Dr. Joshua Hare, Co-Founder & CSO, Longeveron 11.08.2026 23:18
Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, we hear Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talk about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.
Managing Pain While Fighting Cancer...Dr. Lorin Johnson, CSO, Glycyx Therapeutics 04.08.2026 16:43
This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising their care. Dr. Lorin Johnson, CSO of Glycyx Therapeutics explains how a new once-daily pill could help patients manage pain without blocking their treatment.
A New Kind of Flu Shot...Dr. Jeff Stein, President & CEO, Cidara Therapeutics 28.07.2026 18:44
This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.
Insulin-Producing Cells...with no Immunosuppressants?? Dr. Steve Harr, Sana Biotechnology 14.07.2026 14:18
This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without the need for immunosuppressant drugs.
Looking Forward: Biotech in the Balance? Dr. Jeremy Levin, Bioentrepreneur & Former Chair, BIO 21.06.2026 48:19
On this episode of BioTech Nation...The Biotech landscape is ever-evolving - but where are we headed?? Dr. Jeremy Levin, Physician, Bioentrepreneur, and Former Chair of BIO, joins Moira to talk about the future of Biotech from the front lines of the industry - from understanding the global Bioeconomy, to preparing for the next pandemic, and how government policy is impacting innovation. His book...
How 200 Snake Bites Became an Antivenom...Dr. Jake Glanville, Founder, CEO, Chair of Centivax 16.06.2026 34:14
This week on BioTech Nation, a call to a man who survived hundreds of venomous snake bites helps inspire the development of an antivenom vaccine. Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of this Biotech Breakthrough – from the first telephone call through each significant step, all leading to the first breakthrough generalized antive...
Hospital at Home? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 09.06.2026 7:55
On this week's BioTech Nation, Tech Nation Health Chief Correspondent Dr. Daniel Kraft tells us about the trend of "hospital-at-home". As we see the expansion of remote healthcare technologies, could the future of hospital-like care be as on-demand as a food delivery app?
A Not-in-the-Textbooks Discovery for Glioblastoma, Jay Hartenbach & Dr. Will Decker, Diakonos Oncology 29.05.2026 24:04
On this episode of BioTech Nation, Dr. Will Decker and Jay Hartenbach join Moira to talk about Diakonos Oncology's unique approach to cancer immunotherapy, and how a discovery made over two decades ago started it all. Now, with a new drug entering Phase II human trials for Glioblastoma treatment, that discovery could mean a pathway to treating aggressive cancers...
Two Drug Approvals in Two Years...Michael Metzger, CEO, Syndax Pharmaceuticals 28.05.2026 12:31
On this episode of BioTech Nation: how Syndax Pharmaceuticals got two new drugs approved in the last two years, for the treatment of acute myeloid leukemia and graft vs. host disease in both adults and children. CEO Michael Metzger talks to Moira about Syndax's approach to getting the drugs across the finish line, and how they've now set their sights on additional indications and cancer therapies....
Fighting Hard-to-Treat Cancers...Dan Schmitt, President & CEO, Actuate Therapeutics 26.05.2026 15:57
On this episode of BioTech Nation, Dan Schmitt of Actuate Therapeutics talks about a new kind of drug showing positive early results in hard-to-treat cancer - including adult pancreatic cancer, and two pediatric cancers. So, what’s next? Global collaborations, international trials, and efforts into different types of cancer…and they’re showing no sign of slowing down.
A Different Way to Treat Parkinson's...Dr. Jonas Hannestad & Dr. Joanne Taylor, Gain Therapeutics 19.05.2026 12:35
This week on BioTech Nation, Dr. Jonas Hannestad and Dr. Joanne Taylor of Gain Therapeutics join Moira to discuss a different approach to treating Parkinson's. While treatments are typically focused on relieving symptoms, Gain Therapeutics aims to stop progression of the disease itself.
Podcast simili
Replaio non è un editore di podcast; i nomi dei programmi, le copertine e l'audio appartengono ai rispettivi autori e vengono distribuiti tramite feed RSS pubblici